PHI with Infantile neuroaxonal dystrophy
How does this condition affect your private health insurance?
Infantile Neuroaxonal Dystrophy (INAD) is a rare, severe, and progressive neurodegenerative disorder typically manifesting between 6 months and 3 years of age. It is characterized by the degeneration of nerve axons and the formation of spheroid bodies in the brain and peripheral nerves, caused by mutations in the PLA2G6 gene. Initial symptoms include developmental regression, loss of motor skills, hypotonia, and eventually spasticity. As the disease progresses, children experience profound neurological decline, including vision loss (optic atrophy), seizures, feeding difficulties, and respiratory compromise. There is no cure, and treatment focuses on supportive care and symptom management. INAD is ultimately fatal, with most affected children not surviving past early childhood.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Typically, symptoms develop gradually over weeks to months, leading to developmental regression and initial neurological deficits.
Duration of Illness (Lifetime)
Chronic, progressive, and ultimately fatal, usually spanning a few years from symptom onset, rarely exceeding childhood.
Cost of Treatment (Initial)
High (e.g., tens of thousands USD for initial diagnostic workup including genetic testing, MRI, and neurological consultations, plus initial supportive care).
Cost of Treatment (Lifetime)
Very high (e.g., hundreds of thousands to millions USD for ongoing extensive supportive care, therapies, medications for symptom management, specialized equipment, and eventual palliative care).
Mortality Rate
Extremely high; most affected children do not survive beyond early childhood (typically before age 10), often due to complications like respiratory failure or infections.
Risk of Secondary Damages
100%; includes severe physical disability (e.g., quadriplegia, contractures), profound cognitive impairment, vision loss, feeding difficulties, recurrent infections, and respiratory compromise.
Probability of Full Recovery
0%; the disease is relentlessly progressive and irreversible, leading to complete neurological degeneration.
Underlying Disease Risk
Low; INAD is a primary genetic disorder, and there is no specific increased probability of other distinct underlying diseases occurring concurrently at diagnosis beyond general population rates.